310 related articles for article (PubMed ID: 1859894)
1. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.
Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL
Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Carlo-Stella C; Mangoni L; Almici C; Cottafavi L; Meloni G; Mandelli F; Rizzoli V
Blood; 1992 Nov; 80(9):2412-8. PubMed ID: 1421413
[TBL] [Abstract][Full Text] [Related]
3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
Fay JW; Lazarus H; Herzig R; Saez R; Stevens DA; Collins RH; Piñeiro LA; Cooper BW; DiCesare J; Campion M
Blood; 1994 Oct; 84(7):2151-7. PubMed ID: 7919329
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission.
O'Day SJ; Rabinowe SN; Neuberg D; Freedman AS; Soiffer RJ; Spector NA; Robertson MJ; Anderson K; Whelan M; Pesek K
Blood; 1994 May; 83(9):2707-14. PubMed ID: 8167349
[TBL] [Abstract][Full Text] [Related]
10. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
[TBL] [Abstract][Full Text] [Related]
11. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma.
Link H; Boogaerts MA; Carella AM; Ferrant A; Gadner H; Gorin NC; Harabacz I; Harousseau JL; Hervé P; Holldack J
Blood; 1992 Nov; 80(9):2188-95. PubMed ID: 1421390
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
[TBL] [Abstract][Full Text] [Related]
13. Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.
Benboubker L; Cartron G; Roingeard F; Delain M; Degenne M; Linassier C; Hérault O; Truglio D; Bout M; Petit A; Brémond JL; Desbois I; Colombat P; Binet C; Domenech J
Exp Hematol; 2003 Jan; 31(1):89-97. PubMed ID: 12543111
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.
Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Philip T
Blood; 1992 Sep; 80(5):1149-57. PubMed ID: 1515637
[TBL] [Abstract][Full Text] [Related]
15. In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts.
Blazar BR; Kersey JH; McGlave PB; Vallera DA; Lasky LC; Haake RJ; Bostrom B; Weisdorf DR; Epstein C; Ramsay NK
Blood; 1989 Feb; 73(3):849-57. PubMed ID: 2644992
[TBL] [Abstract][Full Text] [Related]
16. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow and blood findings after marrow transplantation and rhGM-CSF therapy.
Ryder JW; Lazarus HM; Farhi DC
Am J Clin Pathol; 1992 May; 97(5):631-7. PubMed ID: 1575207
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.
Rabinowe SN; Neuberg D; Bierman PJ; Vose JM; Nemunaitis J; Singer JW; Freedman AS; Mauch P; Demetri G; Onetto N
Blood; 1993 Apr; 81(7):1903-8. PubMed ID: 8461475
[TBL] [Abstract][Full Text] [Related]
19. In situ radiation sensitivity of recombinant human granulocyte colony-stimulating factor-recruited murine circulating blood and bone marrow progenitors (colony-forming unit [CFU]-granulocyte-macrophage and CFU-megakaryocyte): evidence for possible biologic differences between mobilized blood and bone marrow.
Scheding S; Media JE; KuKuruga MA; Nakeff A
Blood; 1996 Jul; 88(2):472-8. PubMed ID: 8695794
[TBL] [Abstract][Full Text] [Related]
20. Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulocyte-macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin.
Huan SD; Hester J; Spitzer G; Yau JC; Dunphy FR; Wallerstein RO; Dicke K; Spencer V; LeMaistre CF; Andersson BS
Blood; 1992 Jun; 79(12):3388-93. PubMed ID: 1596578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
